• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alvotech

    5/8/25 6:00:33 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    6-K 1 f6k_050825.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-41421

    Alvotech
    (Translation of registrant's name into English)

    9, Rue de Bitbourg,
    L-1273 Luxembourg,
    Grand Duchy of Luxembourg

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    Incorporation by Reference

    Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless expressly set forth by specific reference in such a filing.

    Press Release

    On May 7, 2025, Alvotech issued a earnings press release for Q1 2025 with a business update. A copy of the Press Release is furnished herewith as exhibit 99.1.


    EXHIBIT INDEX

     

    Exhibit Number Description
       
    99.1 Press Release dated May 7, 2025


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Alvotech    
      (Registrant)
       
      
    Date: May 7, 2025     /s/ Tanya Zharov    
      Tanya Zharov
      General Counsel
      
    Get the next $ALVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    9/6/2022$12.00 → $5.00Buy → Sell
    Citigroup
    More analyst ratings

    $ALVO
    Financials

    Live finance-specific insights

    See more
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

      REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. Information on how

      5/2/25 8:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Reports Record Results for 2024 and Provides Business Update

      Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company

      3/26/25 6:34:30 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Alvotech with a new price target

      UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00

      2/14/25 9:00:38 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Barclays with a new price target

      Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously

      1/29/24 7:03:36 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Citigroup with a new price target

      Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously

      10/20/23 7:21:31 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

      REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

      3/27/25 4:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

      REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's ("Xbrane") R&D operations and a biosimilar candidate (the "Acquisition"), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other

      3/20/25 3:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Appoints Interim Chief Quality Officer

      REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou

      2/29/24 4:05:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $ALVO
    SEC Filings

    See more
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

      REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO) (the "Company") a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech

      5/7/25 5:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

      The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025SELARSDI is approved for all indications matching the reference productSELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutica

      5/5/25 7:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alvotech

      SC 13G/A - Alvotech (0001898416) (Subject)

      11/6/24 1:51:59 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alvotech

      SC 13D/A - Alvotech (0001898416) (Subject)

      7/3/24 5:31:12 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alvotech (Amendment)

      SC 13G/A - Alvotech (0001898416) (Subject)

      2/14/24 12:14:38 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 10:44:05 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/8/25 6:00:33 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/7/25 11:58:42 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/5/25 8:00:06 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care